URGN
BUYNeutralComposite
70.90
Technical
96.20
Fundamental
54.00
Rank
—
Price
46.43
Hurst
0.46
As of
Aug 6, 2026
Daily
UroGen Pharma Ltd.
HealthcareBiotechnologyUroGen Pharma Ltd. is a biotechnology company focused on developing treatments for bladder and upper urinary tract cancers. The company offers Zusduri and Jelmyto, approved medications for non-muscle invasive bladder cancer, along with several drug candidates in clinical trials that use its proprietary hydrogel delivery technology to administer chemotherapy directly to affected tissues. UroGen has partnerships with other pharmaceutical companies to expand its pipeline of urological cancer therapies.
Market cap
$1.6B
P/E (trailing)
—
P/E (forward)
12.65
PEG ratio
—
Dividend yield
0.00%
Beta
1.58
52w range
16.50 – 50.81
Return on equity
—
Profit margin
-51.73%
Revenue growth
+199.20%
Earnings growth
—
Price history
1Y: 32.72 (+59.8%) · range 17.00–50.29
Cycle position
24/ 100 cycle scoreENTRY ZONE
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 71 · GOOD SETUP · exit proximity 0
Conviction
49/ 100 · maturity 0%
Buildup.3318
EMA entry setup.4271
Fundamentals.2554
Volume profile
POC
41.13
Price vs POC
-20.5%
Overhead supply
82%
Runway
+4.5%
Value area 32.95–46.84 · 82% of 120d volume overhead · heavy supply
Contributing sources
No source detections in the last 21 days.
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -1.58% | +10.29% | mature |
| 40d | -9.21% | +10.29% | mature |